| HOME >> MEDICINE >> TECHNOLOGY |
We use these non-GAAP financial measures, and in particular non-GAAP operating loss, for internal managerial purposes and incentive compensation for senior management because we believe such measures are one important indicator of the strength and the operating performance of our business. Analysts and investors frequently ask us for this information. We believe that they use these measures to evaluate the overall operating performance of companies in our industry, including as a means of comparing period-to-period results and as a means of evaluating our results with those of other companies.
Our non-GAAP operating loss during the three months ended September 30, 2010 and 2009 was approximately $591,000 and $475,000, respectively. Our non-GAAP operating loss during the six months ended September 30, 2010 and 2009 was approximately $1.2 million and $1.4 million, respectively.Three Months EndedSeptember 30,Six Months EndedSeptember 30,2010 20092010 2009Gross ProfitGAAP gross profit
$2,650,354$2,451,401$5,175,157$4,725,360% of sales
82%82%82%81%Share-based compensation
4,1844,9038,66718,448Depreciation expense
15,76614,15031,46428,299Non-GAAP gross profit
2,670,3042,470,4545,215,2884,772,107Operating ExpensesGAAP operating expenses
3,597,4783,328,4957,047,7186,973,962Share-based compensation
68,241113,909140,024273,014Depreciation expense
57,07457,546114,662115,623Amortization expense
210,682211,503421,450423,316Non-GAAP operating expenses
3,261,4812,945,5376,371,5826,162,009Operating LossGAAP operating loss
(947,124)(877,094)(1,872,561)(2,248,602)Share-based compensation
72,425118,812148,692291,462Depreciation expense
72,84071,696146,126143,922Amortization expense
210,682211,503421,450423,316Non-GAAP operating lo
'/>"/>
| SOURCE Uroplasty, Inc. Copyright©2010 PR Newswire. All rights reserved |